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Associations between variability of glomerular filtration rate
(GFR), death, and cardiovascular events have not been
reported among patients with chronic kidney disease (CKD).
In order to evaluate this, we retrospectively analyzed the risk
of death and de novo heart failure as a function of variability
in estimated GFR among a cohort of 3361 patients with stage
3 CKD. At baseline, patients with greater variability were
younger, more likely to have diabetes, hypertension, and
other comorbid conditions, and were more likely to have
proteinuria and higher estimated GFR. In multivariate-
adjusted Cox proportional hazard models over a median
follow-up of 3.9 years, the risk of death associated with the
highest relative to the lowest quartile of variability was 1.40
(95% confidence interval 1.05–1.87); there was no association
with new-onset heart failure. The mortality association was
independent of serum albumin, proteinuria, baseline
estimated GFR, and the slope of the estimated GFR. Thus,
variability in estimated GFR predicts death among patients
with stage 3 CKD independent of previously reported risk
factors. The prognostic utility of complementing existing risk
stratification metrics with dynamic changes in GFR among
patients with CKD warrants investigation.
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More than 25 million adults in the United States have chronic
kidney disease (CKD); worldwide, estimates range from 7 to
35% of the population, depending on age and criteria used to
define CKD.1,2 Early mortality and excessive cardiovascular
morbidity are the major risks of concern for health providers
caring for these individuals.3 Estimates of glomerular
filtration rate (eGFR) at a single time point are the current
standard for classifying and risk stratifying patients with new-
onset CKD, despite suboptimal test characteristics and poor
risk discrimination.4–6
Recently, several groups have reported an independent
association between the rate of decline in eGFR with death
and cardiovascular morbidity.7–11 The U-shaped relationship
between eGFR change and the risk of death suggests the
possibility that variability itself, regardless of directionality
of eGFR trajectory, may increase the risk of key clinical
outcomes.7,9 The relationship between intra-individual eGFR
variability and outcomes has not been reported, although the
phenomenon of longitudinal variability in renal plasma flow,
serum creatinine, serum cystatin C, and eGFR has been
recognized for some time.12–19
Using a longitudinal electronic database with detailed
demographic, pharmaceutical, clinical, laboratory, and out-
comes information from a large, integrated health-care system,
we investigated the relationship between variability in eGFR
and death among a cohort of adult patients with stage 3 CKD.
We hypothesized that greater variability was associated with
increased mortality risk. As a secondary analysis, we explored
the relationship between eGFR variability and incident heart
failure.
RESULTS
A total of 4349 patients with stage 3 CKD and a minimum of
4 outpatient eGFR values during the 2-year exposure period
were identified; 988 individuals were excluded for prior heart
failure (846), history of end-stage renal disease or prior
hemodialysis therapy (84), history of solid-organ transplan-
tation (77), metastatic cancer (8), and/or active prescription
for immunosuppressive therapy (75). In all, 3361 subjects
were thus eligible and were followed up for a median
(interquartile range) of 3.9 (3.5–4.1) years. At baseline,
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patients with greater variability were younger, more likely to
have diabetes, hypertension, and other comorbid conditions,
and were more likely to have proteinuria and higher eGFR,
among other factors (Table 1).
During follow-up, patients in the highest GFR variability
quartile were more likely to have hospital-acquired acute
kidney injury (14.8% in quartile 4 vs. 6.8% in quartile 1),
although this difference was not significant (P¼ 0.09). Crude
event rates for death and hospitalization for heart failure,
along with incident rate ratios, are reported in Table 2. A
Kaplan–Meier survival curve for death is shown in Figure 1.
In univariate analysis examining the risk associated with
individual study covariates and death, the following were pre-
dictors and were included in multivariate models: age, gender,
smoking status, and hospitalizations during 6 months before
index date; diabetes, hyperlipidemia, coronary artery disease,
and peripheral arterial disease; prescription for beta blocker,
loop or thiazide diuretic, nonsteroidal anti-inflammatory,
or 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG CoA
reductase) inhibitor; body mass index and diastolic blood
pressure; serum albumin and high- and low-density lipo-
protein cholesterol, proteinuria, and baseline eGFR.
Results of the sequential, multivariate Cox proportional
hazard analysis for the primary study outcome of death are
shown in Table 3. The unadjusted risk of death associated
with the highest category of eGFR variability was relatively
stable after adjustment for demographic and comorbid
factors, medication history, and baseline vitals and labs;
inclusion of eGFR slope and hospital-associated acute kidney
injury during follow-up attenuated this risk association
modestly. The fully adjusted (95% confidence interval) risk
was 1.40 (1.05–1.87, P¼ 0.02).
In univariate analysis examining the risk associated with
individual study covariates and heart failure, the following
were predictors and were included in multivariate models:
age and hospitalizations during 6 months before index date;
diabetes, coronary artery disease, and peripheral arterial disease;
prescription for beta blocker, loop diuretic, nonsteroidal anti-
inflammatory, or HMG CoA reductase inhibitor; body mass
index, systolic and diastolic blood pressure; serum albumin
and high-density lipoprotein cholesterol, proteinuria, and
baseline eGFR. There was no association of eGFR variability
with de novo heart failure in both unadjusted and fully
adjusted Cox proportional hazard models (Table 4).
Table 1 | Baseline characteristics of patients with stage 3 CKD, by quartile of eGFR variability
Variable Q1 N=840 Q2 N=840 Q3 N=841 Q4 N=840 P-value
Absolute residual eGFR, ml/min per 1.73m2; mean (s.d.) 1.4 (0.5) 2.6 (0.3) 3.7 (0.4) 6.0 (1.7)
Age, y; median (IQR) 74.0 (69.0–78.0) 73.0 (68.0–77.0) 73.0 (67.0–77.0) 73.0 (66.0–77.0) o0.001
Male, n (%) 343 (40.8) 324 (38.6) 319 (37.9) 299 (35.6) 0.18
White, n (%) 835 (99.4) 831 (98.9) 834 (99.2) 831 (98.9) 0.69
Smoker, n (%) 358 (42.6) 385 (45.8) 373 (44.4) 394 (46.9) 0.31
Hospitalization within 6 months prior, n (%) 17 (2.0) 15 (1.8) 24 (2.9) 37 (4.4) 0.004
Diabetes, n (%) 307 (36.5) 371 (44.2) 365 (43.4) 409 (48.7) o0.001
Hyperlipidemia, n (%) 647 (77.0) 654 (77.9) 641 (76.2) 646 (76.9) 0.89
Coronary artery disease, n (%) 235 (28.0) 250 (29.8) 267 (31.7) 255 (30.4) 0.402
Peripheral arterial disease, n (%) 50 (6.0) 60 (7.1) 67 (8.0) 74 (8.8) 0.14
ACEI or ARB, n (%) 398 (47.4) 400 (47.6) 447 (53.2) 451 (53.7) 0.008
Beta blocker, n (%) 447 (53.2) 455 (54.2) 456 (54.2) 470 (56.0) 0.72
Loop diuretic, n (%) 132 (15.7) 124 (14.8) 174 (20.7) 184 (21.9) o0.001
Thiazide diuretic, n (%) 164 (19.5) 171 (20.4) 187 (22.2) 168 (20.0) 0.54
HMG CoA reductase inhibitor, n (%) 492 (58.6) 493 (58.7) 500 (59.5) 495 (58.9) 0.98
NSAIDs, n (%) 137 (16.3) 145 (17.3) 118 (14.0) 150 (17.9) 0.16
BMIa, kg/m2; median (IQR) 29.5 (26.2–33.9) 30.0 (26.8–34.0) 30.0 (26.5–33.9) 30.3 (26.3–34.4) 0.42
SBP, mmHg; median (IQR) 130.0 (122.0–140.0) 130.0 (120.0– 140.0) 130.0 (122.0– 142.0) 130.0 (120.0– 142.0) 0.18
DBP, mmHg; median (IQR) 72.0 (64.0–80.0) 70.0 (64.0–80.0) 72.0 (65.5–80.0) 70.0 (64.0–79.0) 0.19
Proteinuria, n (%) o0.001
Negative 340 (40.5) 374 (44.5) 391 (46.5) 396 (47.1)
Positive 68 (8.1) 86 (10.2) 103 (12.2) 133 (15.8)
Not ordered 432 (51.4) 380 (45.2) 347 (41.3) 311 (37.0)
HDLb, mg/dl; median (IQR) 49.0 (41.0–60.0) 48.0 (40.0–60.0) 49.0 (40.0–59.0) 51.0 (42.0–60.0) 0.06
LDLc, mg/dl; median (IQR) 95.0 (77.0–118.0) 92.0 (75.0–116.0) 94.0 (76.0–116.0) 93.0 (73.0–115.0) 0.2
eGFR, ml/min per 1.73m2; median (IQR) 46.8 (39.6–53.6) 46.5 (39.9–53.6) 48.2 (41.7–54.1) 51.0 (43.3–58.4) o0.001
Serum albumind, g/dl; median (IQR) 4.2 (4.0–4.4) 4.2 (4.0–4.4) 4.2 (4.0–4.4) 4.2 (3.9–4.4) 0.001
BUN, mg/dl; median (IQR) 23 (19–28) 24 (19–29) 23 (19–29) 22 (18–28) 0.01
AKI during follow-up, n (%) 57 (6.8) 73 (8.7) 71 (8.4) 86 (10.2) 0.09
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; AKI, hospital-associated acute kidney injury; ARB, angiotensin receptor blocker; BMI, body mass index; BUN,
blood urea nitrogen; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HMG CoA
reductase, 3-hydroxy-3-methyl-glutaryl-CoA reductase; IQR, 25–75 interquartile range; LDL, low-density lipoprotein; NSAID, nonsteroidal anti-inflammatory drug; SBP, systolic
blood pressure; y, years.
For age and serum albumin, significant differences across quartiles were due to differences in variance and relatively large sample sizes.
a550 (16.4%) had missing value.
b218 (6.5%) had missing value.
c169 (5.0%) had missing value.
d610 (18.2%) had missing value.
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Fully adjusted Cox models for patient subgroups and the
risk of death associated with greater eGFR variability are shown
in Figure 2. Interactions of eGFR variability with diabetic
status, rate of eGFR change (by tertile) and proteinuria
(positive, negative, or test-not-ordered) were not significant
(P40.10) with the exception of proteinuria (P¼ 0.013).
Sensitivity analyses
In sensitivity analyses using the coefficient of variation of the
eGFR regression line and the residual s.d. (i.e., the s.d. of
points around the eGFR regression line) as alternative
variability measures, fully adjusted Cox models (95%
confidence interval) for death demonstrated risk estimates
similar to the primary analysis: 1.23 (0.91–1.65, P¼ 0.18) and
1.26 (0.94–1.69, P¼ 0.12), respectively. In addition, 40
subjects suffered community-acquired acute kidney injury
during the exposure period; when these eGFR values were
included in the derivation of eGFR residual during the
exposure period, 26 (o1% of the cohort) were reclassified
into a different variability quartile, and the results of the fully
adjusted Cox proportional hazard model for the mortality
outcome were qualitatively unchanged (hazard ratio 1.32,
95% confidence interval 0.99–1.76, P¼ 0.05). Adding blood
urea nitrogen at both baseline and (as a time-dependent
variable) during follow-up to the fully adjusted Cox models
for the mortality outcome likewise did not qualitatively
change the results: hazard ratio 1.38, 95% confidence interval
1.04–1.84, P¼ 0.03.
DISCUSSION
In this analysis of patients with stage 3 CKD receiving care at
a single integrated health-care system, variability of eGFR was
associated with a 40% increased risk of death. This risk was
independent of both traditional (proteinuria, baseline eGFR,
serum albumin, blood pressure, and acute kidney injury) and
nontraditional (rate of eGFR decline) risk factors. We found
no such link between eGFR variability and the development
of new-onset heart failure, suggesting that although dynamic
changes in eGFR may have prognostic value for mortality risk
it does not predict incident heart failure in an at-risk
population, and likely is not an early and sensitive indicator
of heart failure.
These findings suggest that eGFR variability captures
prognostic information distinctly different from that en-
compassed by an estimate of GFR at a single point of time or
the slope of the linear regression line incorporating two or
more eGFR values separated in time (Figure 3). Although
validation of these findings in other CKD populations is
necessary before clinical implementation, it is worth noting
that the utility of incorporating dynamic eGFR changes into
clinical practice depends additionally upon the availability of
an electronic laboratory reporting system and real-time,
automated calculation of these dynamic changes.
Several possible factors might explain the observed
relationship between eGFR variability and death. First,
variability may be related to loss of nephron mass and
limited auto-regulatory reserve, both of which occur with
moderate CKD and which will increase mortality risk.
Notably, however, the association was independent of base-
line eGFR, the rate of GFR decline, and proteinuria,
suggesting that the inclusion of information about dynamic
eGFR change may add prognostic value above and beyond
that attributable to traditional risk markers in CKD. Second,
variability may be a reflection of changes in renal plasma flow
owing to alterations of intravascular volume (owing to
diuretics or other non-pharmaceutical causes), cardiac
compromise, or endothelial dysfunction. We excluded
Table 2 | Unadjusted rates and incident rate ratios for death and heart failure among patients with stage 3 CKD, by quartile of
eGFR variability
Event Q1 N=840 Q2 N=840 Q3 N=841 Q4 N=840
Follow-up time, y; median (IQR) 3.9 (3.5–4.1) 3.9 (3.5–4.1) 3.9 (3.5–4.1) 3.9 (3.5–4.1)
Death
Incidence rate, # events/1000 PY; median (IQR) 29.9 (24.4–36.7) 26.6 (21.4–33.0) 31.3 (25.7–38.2) 41.1 (34.5–49.0)
Incidence rate ratio, median (IQR) Reference 0.89 (0.66–1.20), P=0.44 1.05 (0.79–1.39), P=0.75 1.38 (1.05–1.80), P=0.02
Heart failure requiring hospitalization
Incidence rate, # events/1000 PY; median (IQR) 10.7 (7.6–15.1) 9.7 (6.8–13.9) 11.9 (8.7–16.5) 10.9 (7.8–15.4)
Incidence rate ratio, median (IQR) Reference 0.91 (0.55–1.49), P=0.7 1.11 (0.70–1.78). P=0.65 1.02 (0.63–1.65). P=0.94
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IQR, 25–75 interquartile range; PY, person-years; y, years.
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Figure 1 |Kaplan–Meier curve (time to death) by quartile of
estimated glomerular filtration rate variability.
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subjects with prevalent heart failure from the cohort, and
included in the analysis information about diuretic use and
comorbid diseases, which might negatively impact vascular
health, yet the independent association of eGFR variability
with mortality persisted. It is possible that other confounders
not included in the analysis might explain the findings, and
any explanation remains speculative given the observational
nature of the investigation.
The clinical implications of our findings are potentially
important. Currently, risk assessment is limited to cross-
sectional incorporation of eGFR, although the addition of
albuminuria is likely to add substantially to the quality of risk
counseling nephrologists can provide to their patients.20,21
Beyond this, incorporating both the rate of eGFR decline and
variability of eGFR may further improve the ability to
identify high-risk subjects for increased surveillance and
more aggressive management. Automated laboratory eGFR
reporting, along with the growth of serial longitudinal,
electronic data capture, may provide opportunities for the
incorporation of serial GFR measurement into clinical risk
assessment and counseling. Recent changes in US regulatory
policy may further provide the impetus to explore the
prognostic value of these nontraditional markers.21
This study has both strengths and limitations. Geisinger’s
integrated health-care system and EHR allow for robust
capture of key clinical variables. Although loss-to-follow-up
was not ascertained for individual cohort members, the
annual primary care disenrollment rate at Geisinger was 1.1%
Table 3 | Sequential, multivariate-adjusted Cox proportional hazard models (time to death) by quartile of eGFR variability
among patients with stage 3 CKDa
Q2 Q3 Q4
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value P-valueb
Unadjusted 0.89 (0.66–1.19) 0.43 1.04 (0.78–1.39) 0.77 1.37 (1.05–1.80) 0.02 0.01
Above and demographics, comorbid conditions 0.91 (0.68–1.23) 0.55 1.09 (0.82–1.45) 0.56 1.46 (1.11–1.92) 0.007 0.004
Above and meds-1 0.92 (0.68–1.24) 0.60 1.12 (0.84–1.49) 0.45 1.50 (1.14–1.98) 0.004 0.002
Above and meds-2 0.93 (0.69–1.25) 0.62 1.08 (0.81–1.44) 0.59 1.48 (1.13–1.95) 0.005 0.004
Above and vitals 0.92 (0.69–1.25) 0.61 1.09 (0.81–1.45) 0.58 1.47 (1.12–1.94) 0.006 0.004
Above and labs 0.91 (0.67–1.22) 0.52 1.08 (0.81–1.45) 0.59 1.53 (1.15–2.02) 0.003 0.001
Above and eGFR trajectory 0.90 (0.67–1.22) 0.49 1.09 (0.81–1.45) 0.58 1.49 (1.12–1.98) 0.006 0.003
Above and AKI during follow-up 0.84 (0.62–1.14) 0.26 1.05 (0.78–1.41) 0.74 1.40 (1.05–1.87) 0.02 0.005
Abbreviations: AKI, hospital-associated acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
Demographics and comorbid conditions: age, gender, smoking status, hospitalization 6 months before index date, diabetes, hyperlipidemia, coronary artery disease, and
peripheral arterial disease.
Meds-1: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta blocker, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor, or nonsteroidal anti-
inflammatory drug prescription at baseline.
Meds-2: loop or thiazide diuretic prescription at baseline.
Vitals: baseline body mass index and diastolic blood pressure.
Labs: baseline eGFR, proteinuria, serum albumin, serum high- and low-density lipoprotein.
EGFR trajectory: eGFR slope and its second order.
AKI during follow-up: cumulative hospital-associated AKI events during follow-up period.
aReferent is quartile 1, not shown.
bP-value across quartiles.
Table 4 | Sequential, multivariate-adjusted Cox proportional hazard models (time to first hospitalization for heart failure) by
quartile of eGFR variability among patients with stage 3 CKDa
Q2 Q3 Q4
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value P-valueb
Unadjusted 0.90 (0.55–1.48) 0.68 1.12 (0.70–1.79) 0.65 1.02 (0.63–1.65) 0.94 0.86
Above and demographics, co-morbid conditions 0.86 (0.52–1.42) 0.56 1.06 (0.66–1.70) 0.81 0.91 (0.56–1.48) 0.69 0.83
Above and meds-1 0.86 (0.52–1.41) 0.55 1.05 (0.66–1.69) 0.83 0.92 (0.57–1.50) 0.75 0.85
Above and meds-2 0.85 (0.52–1.40) 0.54 0.98 (0.61–1.58) 0.94 0.86 (0.53–1.41) 0.56 0.88
Above and vitals 0.83 (0.51–1.37) 0.47 0.97 (0.60–1.56) 0.90 0.86 (0.53–1.41) 0.56 0.86
Above and labs 0.81 (0.49–1.34) 0.42 0.98 (0.61–1.58) 0.94 0.91 (0.55–1.51) 0.72 0.84
Above and eGFR trajectory 0.81 (0.49–1.34) 0.41 0.97 (0.60–1.57) 0.91 0.91 (0.55–1.50) 0.71 0.85
Above and AKI during follow-up 0.74 (0.45–1.23) 0.25 0.96 (0.60–1.55) 0.87 0.85 (0.51–1.40) 0.52 0.64
Abbreviations: AKI, hospital-associated acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
Demographics and comorbid conditions: age, hospitalization 6 months before index date, diabetes, coronary artery disease, and peripheral arterial disease.
Meds-1: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta blocker, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor, or nonsteroidal anti-
inflammatory drug prescription at baseline.
Meds-2: loop diuretic prescription at baseline.
Vitals: baseline body mass index, systolic and diastolic blood pressure.
Labs: baseline eGFR, proteinuria, serum albumin, serum high-density lipoprotein.
eGFR trajectory: eGFR slope and its second order.
AKI during follow-up: cumulative hospital-associated AKI events during follow-up period.
aReferent is quartile 1, not shown.
bP-value across quartiles.
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in both 2010 and 2011 (personal communication, Brenda L
Eckrote, Senior Director, Finance, Geisinger Clinic Commu-
nity Practice, to Robert M Perkins, 6 February 2012). For the
older population comprising this study cohort, this rate is
likely even lower. By including a robust set of covariates from
an integrated clinical database, we are able to account for a
large number of potential confounders, which might impact
validity. Confounding by factors not analyzed is nonetheless a
potential limitation. By linking with a national database of
vital statistics, capture of the primary study end point is
complete across the cohort; for the secondary study outcome
of heart failure, this is not necessarily the case given that
information from any hospitalization occurring outside of
Geisinger’s 3-hospital system would not be captured. We
cannot exclude the possibility of bias from patients with
preexisting heart failure entering the cohort owing to coding
errors occurring during the course of routine clinical care.
This type of misclassification would typically be non-
differential, and thus bias the heart failure outcome in the
direction of the null hypothesis for the comparison between
the highest and lowest quartiles of eGFR variability. In
addition, the decision to exclude those individuals prescribed
glucocorticoids at the time of study entry limits the
generalizability of the findings. Finally, the derivation of
eGFR variability used in this analysis is one of several that
might be utilized; testing the relative predictive strengths of
various variability derivations would be a valuable exercise
parallel with efforts to validate the concept in other CKD
populations.
In summary, this study demonstrates the potential for
dynamic changes in eGFR to complement existing prediction
metrics among patients with stage 3 CKD. Validation of these
findings in other populations and in prospective cohorts is
necessary to fully assess the value of dynamic eGFR as a
prognostic tool.
MATERIALS AND METHODS
This retrospective cohort study was reviewed and approved under
‘exempt’ status by the Geisinger Medical Center Institutional Review
Board on 22 April 2011. The data source was EpicCare, Geisinger
Health System’s electronic health record, which contains detailed
demographic, procedural, laboratory, radiographical, vital, and
other clinical data for more than 3.5 million patients receiving care
at any of more than 40 outpatient clinics and 3 inpatient facilities in
Central Pennsylvania.
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Figure 2 |Multivariate Cox proportional hazard models,
estimated glomerular filtration rate (eGFR) variability, and
mortality by patient subgroup. Comparisons within each
subgroup are between eGFR variability quartiles 4 vs. 1 (Q4 vs.
Q1). All models shown are fully adjusted for age, gender, smoking
status, hospitalization 6 months before index date, diabetes,
hyperlipidemia, coronary artery disease, and peripheral arterial
disease; prescription at baseline for beta blocker, HMG CoA
reductase inhibitor, nonsteroidal anti-inflammatory, loop or
thiazide diuretic, angiotensin-converting enzyme inhibitor, or
angiotensin receptor blocker; baseline body mass index and
diastolic blood pressure; baseline eGFR, proteinuria, serum
albumin, serum high- and low-density lipoprotein; eGFR slope and
its second order; and cumulative hospital-associated acute kidney
injury during follow-up. We tested the interaction of eGFR
variability with diabetic status, tertile of rate of eGFR change, and
proteinuria (positive, negative, or test-not-ordered); P-values were
0.95, 0.13, and 0.013, respectively. CL, confidence limits; HR,
hazard ratio; LCL, lower confidence limit; UCL, upper confidence
limit.
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Study population
Patients eligible for the study included adults aged 18–88 years as of
1 January 2004, and alive on 31 December 2006, with baseline stage
3 CKD, defined as two outpatient GFR values between 30 and
59ml/min per 1.73m2, separated by at least 90 but no more than
730 days. In addition, a minimum of two additional outpatient GFR
values within a 2-year window were required, such that all eligible
cohort members had a minimum of four GFR readings during the
exposure period (1 January 2004 through 31 December 2006). The
study index date was 31 December 2006.
GFR was estimated from serum creatinine using the CKD-EPI
(echo planar imaging) estimating equation.22 Serum creatinine was
measured at a single Geisinger lab using the isotope dilution/mass
spectroscopy—traceable Roche enzymatic method throughout the
entirety of the study period.23 Instrument calibration at Geisinger
labs is performed according to manufacturer’s specifications. No
changes in calibration techniques occurred during the study period.
Patients were excluded for any history of heart failure, history of
end-stage renal disease or prior dialysis therapy, history of solid-
organ transplantation, metastatic cancer, or an active prescription
for immunosuppressive therapy during the exposure window.
Operational definitions for the exclusion criteria are available as
supplementary material (Supplementary Table S1 online).
Exposure
The study exposure was the mean absolute value of the residual of
the eGFR regression line. The eGFR residual, as applied here, was
defined as the difference between the obtained clinical eGFR value at
a given time and the eGFR value estimated by the linear regression
line at the same time point; the regression line was obtained by
incorporating outpatient eGFR values during the exposure window.
First, eGFR was calculated using outpatient serum creatinine values
from the exposure period and the CKD-EPI estimating equation.
The patient-specific slope of eGFR was then derived, and the
residual (i.e., the difference between observed and slope-predicted
eGFR) value was calculated for each data point. The mean absolute
residual value was then calculated, and patients were stratified by
quartiles. Community-acquired acute kidney injury (defined as a
50% increase in serum creatinine occurring in the outpatient setting
and within 30 days of another outpatient serum creatinine result,
without hospital admission) was analyzed in sensitivity analyses.
Serum creatinine values meeting this criterion were not used to
derive eGFR slope or residual values in the primary analysis; a
sensitivity analysis in which these values were incorporated into the
derivation of eGFR residuals was performed (see below).
Outcomes
Follow-up for study outcomes occurred through 31 March 2011.
The primary study outcome was death. Information on vital status
for Geisinger primary care recipients is updated monthly by
institutional query of the Social Security Administration’s data set
through the National Technical Information Service.24 The second-
ary study outcome was new-onset heart failure, defined as a primary
or secondary hospital discharge diagnosis of congestive heart failure.
Study covariates
Variables considered included demographic information, smoking
status, medications active at the time of the index date, comorbid
conditions, vital signs, and labs. Medication status was not updated
after entry into the cohort. Most proximal and prior (to index date)
labs and vital signs were used. If a value was not available during the
12 months before the index date, it was considered not ordered for
laboratory tests, and missing for vitals. Comorbid conditions were
coded if present on the patient’s medical problem list during the
exposure period, or if an ICD-9-CM code was documented in
association with at least two outpatient encounters during the
exposure period. In addition to baseline eGFR, the slope of eGFR
change was incorporated as a model covariate. Proteinuria was defined
in a binary fashion, i.e., any semiquantitative dipstick analysis result of
30mg/dl or greater, urinary protein-to-creatinine ratio of 0.2mg
protein/g creatinine or greater, or a 24-h urine protein of at least 300-
mg protein was considered positive. Hospital-associated acute kidney
injury (defined by an increase of 50% or more in serum creatinine
during a hospitalization for any cause, with the baseline serum
creatinine defined as the lowest recorded value between 90 days before
the index admission and the hospital discharge date) occurring after
the index date was included as a time-dependent covariate in survival
models.25 Operational definitions for study covariates are available as
supplementary material (Supplementary Table S1 online). As a
sensitivity analysis (see below), blood urea nitrogen values (last value
during the exposure window, as well as all values during the follow-up
period) were added to the multivariate-adjusted mortality model.
Statistical analysis
Data are presented as mean and s.d., or median and interquartile
range, for continuous variables, and as frequency and percentage for
categorical variables. For any continuously measured covariate with
missing baseline values, we used multiple imputation for missing lab
values, to limit bias. Ten imputed data sets were created and used for
these analyses. For proteinuria, a dummy variable was created to
indicate whether or not this test was ordered.26 Baseline comparisons
across quartiles of eGFR variability were made using the Kruskal–-
Wallis nonparametric and Pearson’s w2 tests, as appropriate. Rates of
death and heart failure were determined for each group and
expressed as the number of events per 1000 person-years. A Poisson
regression model was used to estimate the mortality and heart failure
rates across groups and expressed as incident rate ratios. Unadjusted
estimates of survival were analyzed using the Kaplan–Meier method.
Time until death and heart failure were then analyzed using
multivariate-adjusted Cox proportional hazard regression. Variables
significant at Po0.10 in the univariate analysis, or previously
associated with death or heart failure among patients with CKD,
were included in the models. In preliminary analyses, the long-
itudinal eGFR pattern followed a quadratic shape; therefore, the
quadratic term was added as a separate covariate along with the
linear slope to the survival models. Subgroup analyses (pre-specified
by diabetic status, proteinuria status, and slope of eGFR) were
performed to examine the stability of the observed associations for
the mortality outcome. Slope of eGFR for the purposes of subgroup
classification was defined by tertile of eGFR slope, derived using all
outpatient serum creatinine values during the exposure-defining
window. Interaction testing across the subgroups was performed.
Sensitivity analyses
To assess the stability and robustness of the primary outcome
analysis, we reran all analyses after calculating variability using the
coefficient of variation of the regression line for eGFR, and again
using the residual s.d. As an additional sensitivity analysis, we
analyzed the association between eGFR variability and death after
including those eGFR values qualifying for community-acquired
acute kidney injury into the derivation of eGFR variability during
the exposure window. Finally, in a separate sensitivity analysis, we
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included blood urea nitrogen (last value during the exposure
window, as well as all values during the follow-up period in a time-
dependent manner) to the multivariate-adjusted mortality model
because of its recognized mortality association.27
All analyses were performed using SAS version 9.2 (SAS
Corporation, Cary, NC).
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